Matthias H. Tschöp is a notable leader in the diabetes field, currently serving as the CEO and Spokesperson for the Management at Helmholtz Munich, as well as the 'Alexander von Humboldt' Professor at the Technical University of Munich. With a vision to establish Munich as a global hub for biomedical research, he aims to address evolving health challenges. He has excelled in diabetes and obesity research, pioneering the discovery of the hunger hormone ghrelin and the breakthrough gut hormone polyagonists, which have paved the way for improved weight reduction and blood sugar control in type 2 diabetes. His leadership is evidenced by his instrumental role in the approval of Tirzepatide (Mounjaro), the first polyagonist drug approved for use, along with ongoing trials for 10 other polyagonists. With a diverse background that includes medical practice, research, and industry experience, Tschöp's leadership has transformed institutions like the Helmholtz Diabetes Center and propelled advancements in diabetes research and treatment.